Home > Boards > US Listed > Medical - Drugs >

Precipio Inc. (PRPO)

Add PRPO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 4/6/2020 1:11:09 PM - Followers: 90 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).



New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437
E-mail: investorrelations@transgenomic.com

SEC Filings:

Press Releases:

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#3328   good call pop to .94 drop to .60 PRPO [SMART MONEY] 04/06/20 01:11:09 PM
#3327   S1 filed be careful stock1ace1 04/06/20 10:37:37 AM
#3326   PRPO news/halt https://www.marketwatch.com/press-release/precipio-launches-new-h [SMART MONEY] 04/06/20 10:11:17 AM
#3325   buying heavily under 2 bucks. Lots of naysaying PennyStockTrader2 01/31/20 02:35:25 PM
#3324   your charting skills still suck SidVicious 01/15/20 10:47:23 AM
#3323   * * $PRPO Video Chart 01-14-2020 * * ClayTrader 01/14/20 06:06:40 PM
#3322   Boom wupsumskul 12/20/19 09:33:02 AM
#3321   Precipio granted International patent number WO2019241314 titled "CULTURE wupsumskul 12/19/19 04:03:08 PM
#3320   Read my post again. boston127 12/18/19 12:18:58 PM
#3319   well, no. See, you fail to understand that SidVicious 12/18/19 07:37:18 AM
#3318   Detecting cancer is the only way boston127 12/18/19 01:10:55 AM
#3317   This won’t defeat cancer. It will only detect it. SidVicious 12/17/19 10:56:14 PM
#3316   Got in today. boston127 12/17/19 12:33:30 PM
#3315   News: $PRPO Precipio Announces First IV-Cell Commercial Order whytestocks 12/17/19 11:45:22 AM
#3314   News: $TBIO Translate Bio Announces Executive Leadership Appointments whytestocks 12/12/19 11:30:10 PM
#3313   Filled yankees18 11/14/19 12:31:30 PM
#3312   Yankees Suck!! Dean The Great 10/24/19 05:51:40 AM
#3311   In conference call today Iian expect Precipio to cash_cow1 10/10/19 08:40:37 PM
#3310   2.41 PRPO starting to smell [SMART MONEY] 10/10/19 10:36:31 AM
#3309   Looks like its gonna rally into close holding up stock1ace1 10/10/19 09:32:29 AM
#3308   Trying to 2.54s p/m :D stock1ace1 10/10/19 09:11:24 AM
#3307   Not 5, not 10, BUT 50 NEW CUSTOMERS. crudeoil24 10/10/19 08:30:48 AM
#3306   6 Mill o/s stock1ace1 10/10/19 08:28:16 AM
#3305   9/30 news was huge 1st contract/customer 750k$ cash stock1ace1 10/10/19 08:26:02 AM
#3304   Have u seen recent news ? stock1ace1 10/10/19 08:24:23 AM
#3303   Maybe tomorrow! crudeoil24 10/10/19 08:14:17 AM
#3302   *** Conference call today 5pm *** I. Precipio Announces Shareholder stock1ace1 10/10/19 07:50:09 AM
#3301   Great call right after you posted that news stock1ace1 10/09/19 11:00:01 PM
#3300   * * $PRPO Video Chart 10-09-2019 * * ClayTrader 10/09/19 05:39:01 PM
#3299   Conference call tomorrow 5 pm ~> Precipio Announces stock1ace1 10/09/19 04:45:59 PM
#3298   Big Contracts Coming Read ~> Based on current stock1ace1 10/09/19 03:42:51 PM
#3297   LOL! Great come back...and true. SidVicious 10/04/19 06:55:14 AM
#3296   Pumper still run their mouths. That counts right? Soulman856 10/02/19 05:21:12 PM
#3295   Big boards being destroyed by shorts...nothing runs anymore... yankees18 10/02/19 05:18:17 PM
#3294   2.87 and out thanks again! buypumps 09/27/19 03:21:12 PM
#3293   Come on girl push thru 2.85 this cash buypumps 09/27/19 01:45:46 PM
#3292   Up to 2.83 she warming up boys and buypumps 09/27/19 01:17:17 PM
#3291   Grabbed 2500 at 2.72 for a pop! Little buypumps 09/27/19 12:56:02 PM
#3290   Caution dilution machine turned on! August 21 prospectus! buypumps 09/27/19 10:03:21 AM
#3289   150% avg volume already UOENO 09/27/19 09:13:12 AM
#3288   better than your long, that's for sure! If SidVicious 09/27/19 08:16:17 AM
#3287   Always take profits you will learn! Quick fast buypumps 09/26/19 04:02:12 PM
#3286   How does power hour look here ?? Breakout kevgan9 09/26/19 01:22:28 PM
#3285   Maybe. But today's news was pure fluff. KOmani 09/26/19 12:34:39 PM
#3284   it depends on what time frame you are PennyStockTrader2 09/26/19 12:32:21 PM
#3283   This is the next BPTH 1000% runner watch! MonstaGains 09/26/19 12:26:50 PM
#3282   Great enjoy me quick cash short risk nice buypumps 09/26/19 12:24:55 PM
#3281   Multi-million dollar contracts coming soon!!!! MonstaGains 09/26/19 12:22:19 PM
#3280   Minimum $5 to $6 coming today and $10+ tomorrow MonstaGains 09/26/19 12:21:44 PM
#3279   Out 3.36 no need to be greedy! buypumps 09/26/19 12:19:21 PM